Last reviewed · How we verify
Advanced renal cell carcinoma (RCC) as a first-line treatment
Approved treatments
- Axitinib (AG-013736) · Pfizer
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Advanced renal cell carcinoma (RCC) as a first-line treatment patent landscape — cliff calendar, originator estates, attackable patents
- Advanced renal cell carcinoma (RCC) as a first-line treatment treatment landscape brief
- Advanced renal cell carcinoma (RCC) as a first-line treatment treatment updates RSS
Frequently asked questions about Advanced renal cell carcinoma (RCC) as a first-line treatment
What drugs treat Advanced renal cell carcinoma (RCC) as a first-line treatment?
Tracked treatments include Axitinib (AG-013736).
What is the treatment for Advanced renal cell carcinoma (RCC) as a first-line treatment?
Standard treatment for Advanced renal cell carcinoma (RCC) as a first-line treatment includes Axitinib (AG-013736). See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Advanced renal cell carcinoma (RCC) as a first-line treatment patent cliff · Advanced renal cell carcinoma (RCC) as a first-line treatment CI report
- Treatment: Axitinib (AG-013736) · Pfizer
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing